Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 in Combination with Active Myeloma Agents In Vitro and In Vivo

被引：0

作者：

Sanchez, Eric ^{[1
]}

Porter, Autumn ^{[2
]}

Li, Mingjie ^{[1
]}

Wang, Cathy ^{[1
]}

Smith, Emily ^{[2
]}

Soof, Camilia ^{[1
]}

Director, Chelsea ^{[2
]}

Tang, George ^{[1
]}

Chen, Haiming ^{[1
]}

Berenson, James ^{[1
]}

机构：

[1] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA

[2] Inst Myeloma & Bone Canc Res, Hollywood, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期

关键词：

D O I：

10.1016/j.clml.2017.03.089

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS-087 (d)

引用

页码：E49 / E50

页数：2

共 50 条

[31] Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.
Tai, Yu-Tzu
Kim, Kihyun
Li, Xian-Feng
Fulciniti, Mariateresa
Song, Weihua
Nahar, Sabikun
Burger, Peter
Rumizen, Mathew J.
Podar, Klaus
Chauhan, Dharminder
Hideshima, Teru
Schlossman, Robert L.
Munshi, Nikhil C.
Richardson, Paul
Clark, Ann
Ogden, Janet
Andreas, Goutopoulos
Rastelli, Luca
Anderson, Kenneth C.
[J]. BLOOD, 2009, 114 (22) : 1480 - 1480
[32] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)
Forero-Torres, A.
Barr, P.
Diefenbach, C.
Sher, T.
Schaub, R.
Zhou, L.
Pulini, J.
Leopold, L.
Spear, M.
Talpaz, M.
Phillips, T.
[J]. HAEMATOLOGICA, 2015, 100 : 112 - 112
[33] Arsenic trioxide shows synergistic anti-myeloma effects when combined with bortezomib and melphalan in vitro and helps overcome resistance of multiple myeloma cells to these treatments in vivo.
Campbell, RA
Chen, HM
Zhu, DC
Santos, JC
Bonavida, B
Pang, S
Said, J
Berenson, JR
[J]. BLOOD, 2004, 104 (11) : 677A - 677A
[34] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)
Phillips, T.
Forero-Torres, A.
Sher, T.
Diefenbach, C.
Talpaz, M.
Scherle, P.
Schaub, R.
Zhou, L.
Pulini, J.
Leopold, L.
Spear, M.
Barr, P.
[J]. HAEMATOLOGICA, 2015, 100 : 110 - 110
[35] PTC-209, A TRANSCRIPTIONAL SMALL MOLECULE INHIBITOR OF BMI-1, DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO
Bolomsky, A.
Ludwig, H.
[J]. HAEMATOLOGICA, 2015, 100 : 77 - 78
[36] Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo
Das, Deepika Sharma
Ray, Arghya
Song, Yan
Richardson, Paul
Trikha, Mohit
Chauhan, Dharminder
Anderson, Kenneth C.
[J]. BLOOD, 2015, 126 (23)
[37] The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases
Kikuchi, Jiro
Yamada, Satoshi
Koyama, Daisuke
Wada, Taeko
Nobuyoshi, Masaharu
Izumi, Tohru
Akutsu, Miyuki
Kano, Yasuhiko
Furukawa, Yusuke
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (35) : 25593 - 25602
[38] In vitro and ex vivo anti-myeloma effects of nanocomposite As4S4/ZnS/Fe3O4
Danka Cholujova
Lenka Koklesova
Zdenka Lukacova Bujnakova
Erika Dutkova
Zuzana Valuskova
Patricia Beblava
Anna Matisova
Jan Sedlak
Jana Jakubikova
[J]. Scientific Reports, 12
[39] In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
Pozzi, Samantha
Fulciniti, Mariateresa
Yan, Hua
Vallet, Sonia
Eda, Homare
Patel, Kishan
Santo, Loredana
Cirstea, Diana
Hideshima, Teru
Schirtzinge, Linda
Kuhstoss, Stuart
Anderson, Kenneth C.
Munshi, Nikhil
Scadden, David
Kronenberg, Henry M.
Raje, Noopur
[J]. BONE, 2013, 53 (02) : 487 - 496
[40] In vitro and ex vivo anti-myeloma effects of nanocomposite As4S4/ZnS/Fe3O4
Cholujova, Danka
Koklesova, Lenka
Bujnakova, Zdenka Lukacova
Dutkova, Erika
Valuskova, Zuzana
Beblava, Patricia
Matisova, Anna
Sedlak, Jan
Jakubikova, Jana
[J]. SCIENTIFIC REPORTS, 2022, 12 (01)

← 1 2 3 4 5 →